Skip to main content

Lymphocyte Receptor Pathways

  • Chapter
  • First Online:

Abstract

The two types of lymphocytes, B and T, which are, respectively, responsible for humoral and cell-mediated immunity, express membrane receptors in relation to their immune functions: their task involves antigen recognition and elaboration of appropriate responses. Toward a multitude of possible antigens, a huge diversity in recognition structures is necessary: it is represented by the membrane immunoglobulins in charge of their binding. Contrasting to this diversity is the relative uniformity of receptor-associated proteins that are in charge of the elaboration of the response and are bound to the receptor itself by non-covalent bonds. Downstream the receptor complex, several pathways that have been studied in other chapters may be implemented to regulate lymphocyte proliferation and migration; they mainly involve the activation of cytoplasmic kinases, the generation of second messengers and the activation of small G-proteins.

We cannot summarise all immunology in a single chapter, but only extract some information related to the modalities of lymphocyte signalling, from receptors to effectors, trying to identify the features that cancer cells can utilise to reach their own goals and how these features can serve as potential targets for anticancer treatments.

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Further Reading

  • Anders K, Blankenstein T. Molecular pathways: comparing the effects of drugs and T cells to effectively target oncogenes. Clin Cancer Res. 2013;19:320–6.

    Article  CAS  PubMed  Google Scholar 

  • Brezski RJ, Monroe JG. B-cell receptor. Adv Exp Med Biol. 2008;640:12–21.

    Article  CAS  PubMed  Google Scholar 

  • Burbach BJ, Medeiros RB, Mueller KL, Shimizu Y. T-cell receptor signaling to integrins. Immunol Rev. 2007;218:65–81.

    Article  CAS  PubMed  Google Scholar 

  • Ceeraz S, Nowak EC, Noelle RJ. B7 family checkpoint regulators in immune regulation and disease. Trends Immunol. 2013;34:556–63.

    Article  CAS  PubMed  Google Scholar 

  • Cronin SJ, Penninger JM. From T-cell activation signals to signaling control of anti-cancer immunity. Immunol Rev. 2007;220:151–68.

    Article  CAS  PubMed  Google Scholar 

  • Dal Porto JM, Gauld SB, Merrell KT, Mills D, Pugh-Bernard AE, Cambier J. B-cell antigen receptor signaling. Mol Immunol. 2004;41:599–613.

    Article  CAS  PubMed  Google Scholar 

  • Gomez-Rodriguez J, Readinger JA, Viorritto IC, Mueller KL, Houghtling RA, Schwartzberg PL. Tec kinases, actin, and cell adhesion. Immunol Rev. 2007;218:45–64.

    Article  CAS  PubMed  Google Scholar 

  • Hendriks RW, Yuvaraj S, Kil LP. Targeting Bruton’s tyrosine kinase in B cell malignancies. Nat Rev Cancer. 2014;14:219–32.

    Article  CAS  PubMed  Google Scholar 

  • Katzav S. Flesh and blood: the story of Vav1, a gene that signals in hematopoietic cells but can be transforming in human malignancies. Cancer Lett. 2007;255:241–54.

    Article  CAS  PubMed  Google Scholar 

  • Kershaw MH, Westwood JA, Darcy PK. Gene-engineered T cells for cancer therapy. Nat Rev Cancer. 2013;13:525–41.

    Article  CAS  PubMed  Google Scholar 

  • Kirkwood JM, Tarhini AA, Panelli MC, Moschos SJ, Zarour HM, Butterfield LH, Gogas HJ. Next generation of immunotherapy for melanoma. J Clin Oncol. 2008;26:3445–55.

    Article  CAS  PubMed  Google Scholar 

  • Küppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer. 2005;5:251–62.

    Article  PubMed  Google Scholar 

  • Peggs KS, Quezada SA, Allison JP. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev. 2008;224:141–65.

    Article  CAS  PubMed  Google Scholar 

  • Rojo JM, Bello R, Portolés P. T-cell receptor. Adv Exp Med Biol. 2008;640:1–11.

    Article  CAS  PubMed  Google Scholar 

  • Smith-Garvin JE, Koretzky GA, Jordan MS. T-cell activation. Annu Rev Immunol. 2009;27:591–619.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Xue S, Gillmore R, Downs A, Tsallios A, Holler A, Gao L, Wong V, Morris E, Stauss HJ. Exploiting T-cell receptor genes for cancer immunotherapy. Clin Exp Immunol. 2005;139:167–72.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Yao S, Zhu Y, Chen L. Advances in targeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discov. 2013;12:130–46.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Young RM, Staudt LM. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov. 2013;12:229–43.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Robert, J. (2015). Lymphocyte Receptor Pathways. In: Textbook of Cell Signalling in Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-14340-8_13

Download citation

Publish with us

Policies and ethics